Shots:

• The P-II (NCT02130882) study involves assessing of Fasenra (benralizumab-30mg- q4w) vs PBO in 20 patients with HES who had at least 1-000 eosinophils/µL of blood
• The P-II (NCT02130882) clinical study results: @12wks. reduction in absolute blood eosinophil counts >50% (90% vs 30%); @48wks.maintained reduction in eosinophil counts (74%); patients taper off other HES therapies (64%)- Published at New England Journal of Medicine
• Fasenra (benralizumab- SC- q4w) is a mAb targeted IL-5 receptor presented at the surface of eosinophils and has also received approval for eosinophilic asthma in US- EU- Japan with FDA’s ODD for HES. Kyowa Hakko in-licensed Fasenra from AZ

Ref: AstraZeneca | Image: AstraZeneca